Simulations Plus, Inc. (SLP)
$
16.05
+0.65 (4.05%)
Key metrics
Financial statements
Free cash flow per share
0.6479
Market cap
310 Million
Price to sales ratio
3.8560
Debt to equity
0.0058
Current ratio
5.1106
Income quality
-0.2248
Average inventory
0
ROE
-0.3717
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Simulations Plus, Inc. develops drug discovery and development software that leverages artificial intelligence and machine learning technologies for modeling, simulation, and prediction of molecular properties globally. The company reported an earnings per share (EPS) of $0.50 indicating its profitability on a per-share basis. The income before tax ratio stands at 0.18 reflecting the pre-tax margin, while the cost of revenue amounts to $26,862,000.00 showcasing its production and operational expenses. The company's EBITDA is reported at $11,796,000.00 serving as a key indicator of operational profitability. Additionally, the gross profit ratio is 0.62 highlighting the efficiency of the company's production and sales operations. Operating through segments such as Simulations Plus, Cognigen, DILIsym, and Lixoft, the company provides products like GastroPlus, which simulates drug interactions in humans and animals, along with various simulation tools like DDDPlus and MembranePlus. Moreover, it offers advanced mechanistic and mathematical models through products like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Simulations Plus also features an Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor, and MedChem Designer, supplemented by MonolixSuite and PKPlus modeling products. Alongside, it offers consulting and contract research services that support pharmacometrics studies and regulatory submissions. Currently, the stock is affordable at $15.25 making it suitable for budget-conscious investors. It has a low average trading volume of 520,179.00 indicating lower market activity. With a market capitalization of $323,040,116.00 the company is classified as a small-cap player. Simulations Plus is a key player in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field. As the company continues to make strides in drug development technologies, it presents opportunities for investors looking to engage in a forward-thinking and strategically positioned entity in the life sciences domain.
Investing in Simulations Plus, Inc. (SLP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Simulations Plus, Inc. stock to fluctuate between $12.39 (low) and $37.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-10-20, Simulations Plus, Inc.'s market cap is $323,040,116, based on 20,127,110 outstanding shares.
Compared to Nvidia Corp, Simulations Plus, Inc. has a Lower Market-Cap, indicating a difference in performance.
Simulations Plus, Inc. pays dividends. The current dividend yield is 0.60%, with a payout of $0.06 per share.
To buy Simulations Plus, Inc. (SLP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SLP. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Simulations Plus, Inc.'s last stock split was 2:1 on 2007-10-02.
Revenue: $70,013,000 | EPS: $0.50 | Growth: 0%.
Visit https://www.simulations-plus.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $67.59 (2022-08-08) | All-time low: $12.39 (2025-07-18).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/simulations-plus-inc-class-action-lawsuit.
globenewswire.com
NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f.
globenewswire.com
NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
prnewswire.com
NEW YORK , Oct. 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/simulations-plus-inc-class-action-lawsuit.
globenewswire.com
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
globenewswire.com
NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/simulations-plus-inc-class-action-lawsuit.
globenewswire.com
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
globenewswire.com
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the federal securities laws. If you invested in Simulations Plus, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/simulations-plus-inc-class-action-lawsuit.
See all news